Issue Date: April 28, 2008
GSK And Regulus Seal RNA Drug Pact
GlaxoSmithKline has teamed up with Regulus Therapeutics, a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, to discover and develop microRNA-targeted drugs. Regulus will develop microRNA antagonists against four targets related to inflammatory disease through clinical proof of concept; GSK will then have the option to license those drugs for further development. GSK will pay Regulus $20 million up front plus up to $144.5 million in milestones for each target developed in the deal. MicroRNAs are small single-stranded RNAs that regulate the expression of many human genes.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society